在线日韩日本国产亚洲丨少妇伦子伦情品无吗丨欧美性猛交xxxx免费看蜜桃丨精品人妻系列无码一区二区三区丨亚洲精品无码不卡在线播放

Your Good Partner in Biology Research

重組蛋白

產(chǎn)品名稱 貨號(hào) 規(guī)格
Recombinant Xylella fastidiosa 50S ribosomal protein L16 (rplP) CSB-YP533832XBM
CSB-EP533832XBM
CSB-BP533832XBM
CSB-MP533832XBM
CSB-EP533832XBM-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Xylella fastidiosa 30S ribosomal protein S13 (rpsM) CSB-YP533833XBM
CSB-EP533833XBM
CSB-BP533833XBM
CSB-MP533833XBM
CSB-EP533833XBM-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Xylella fastidiosa 50S ribosomal protein L17 (rplQ) CSB-YP533834XBM
CSB-EP533834XBM
CSB-BP533834XBM
CSB-MP533834XBM
CSB-EP533834XBM-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Xylella fastidiosa DNA-directed RNA polymerase subunit beta (rpoB), partial CSB-YP533835XBM
CSB-EP533835XBM
CSB-BP533835XBM
CSB-MP533835XBM
CSB-EP533835XBM-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Xylella fastidiosa Ribosomal RNA large subunit methyltransferase L (rlmL), partial CSB-YP533836XBM
CSB-EP533836XBM
CSB-BP533836XBM
CSB-MP533836XBM
CSB-EP533836XBM-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Xylella fastidiosa ATP-dependent Clp protease adapter protein ClpS (clpS) CSB-YP533837XBM
CSB-EP533837XBM
CSB-BP533837XBM
CSB-MP533837XBM
CSB-EP533837XBM-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Xylella fastidiosa 50S ribosomal protein L13 (rplM) CSB-YP533838XBM
CSB-EP533838XBM
CSB-BP533838XBM
CSB-MP533838XBM
CSB-EP533838XBM-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Xylella fastidiosa Bifunctional purine biosynthesis protein PurH (purH), partial CSB-YP533839XBM
CSB-EP533839XBM
CSB-BP533839XBM
CSB-MP533839XBM
CSB-EP533839XBM-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Methylobacterium sp. Anthranilate phosphoribosyltransferase (trpD) CSB-YP533840MTE
CSB-EP533840MTE
CSB-BP533840MTE
CSB-MP533840MTE
CSB-EP533840MTE-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Methylobacterium sp. Sulfite reductase [NADPH] hemoprotein beta-component (cysI), partial CSB-YP533841MTE
CSB-EP533841MTE
CSB-BP533841MTE
CSB-MP533841MTE
CSB-EP533841MTE-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Methylobacterium sp. Nitrogenase iron protein (nifH) CSB-YP533842MTE
CSB-EP533842MTE
CSB-BP533842MTE
CSB-MP533842MTE
CSB-EP533842MTE-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Methylobacterium sp. D-amino acid dehydrogenase small subunit (dadA) CSB-YP533843MTE
CSB-EP533843MTE
CSB-BP533843MTE
CSB-MP533843MTE
CSB-EP533843MTE-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Methylobacterium sp. Periplasmic nitrate reductase (napA), partial CSB-YP533844MTE
CSB-EP533844MTE
CSB-BP533844MTE
CSB-MP533844MTE
CSB-EP533844MTE-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Methylobacterium sp. Serine--tRNA ligase (serS) CSB-YP533845MTE
CSB-EP533845MTE
CSB-BP533845MTE
CSB-MP533845MTE
CSB-EP533845MTE-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Methylobacterium sp. Lipoprotein signal peptidase (lspA), partial CSB-YP533846MTE1
CSB-EP533846MTE1
CSB-BP533846MTE1
CSB-MP533846MTE1
CSB-EP533846MTE1-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Methylobacterium sp. Coenzyme PQQ synthesis protein E (pqqE) CSB-YP533847MTE
CSB-EP533847MTE
CSB-BP533847MTE
CSB-MP533847MTE
CSB-EP533847MTE-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Methylobacterium sp. UDP-N-acetylmuramate--L-alanine ligase (murC) CSB-YP533848MTE
CSB-EP533848MTE
CSB-BP533848MTE
CSB-MP533848MTE
CSB-EP533848MTE-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Methylobacterium sp. Protein RecA (recA) CSB-YP533849MTE
CSB-EP533849MTE
CSB-BP533849MTE
CSB-MP533849MTE
CSB-EP533849MTE-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Methylobacterium sp. Aspartyl/glutamyl-tRNA (Asn/Gln) amidotransferase subunit C CSB-YP533850MTE
CSB-EP533850MTE
CSB-BP533850MTE
CSB-MP533850MTE
CSB-EP533850MTE-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Methylobacterium sp. DNA-directed RNA polymerase subunit alpha (rpoA) CSB-YP533851MTE
CSB-EP533851MTE
CSB-BP533851MTE
CSB-MP533851MTE
CSB-EP533851MTE-B
20μg/100μg/1mg(1mg*1 or 500ug*2)

有用資源

什么是重組蛋白?

重組蛋白是一種可操縱的蛋白質(zhì)形式,可以通過多種方式產(chǎn)生大量蛋白質(zhì)、修改基因序列和制造有用的商業(yè)產(chǎn)品。重組蛋白的技術(shù)資源在重組蛋白的開發(fā)過程中,除了表達(dá)系統(tǒng)之外,還面臨著一系列令人困惑的選擇,如表達(dá)載體的選擇、表達(dá)蛋白的長度(全長或部分)、是否帶標(biāo)簽等。在生產(chǎn)重組蛋白時(shí),你必須做出很多決定。如果你選擇的明智,你將獲得高質(zhì)量的重組蛋白,后續(xù)的實(shí)驗(yàn)更有可能成功。但是如果你做了錯(cuò)誤的決定,你可能得不到你所需要的重組蛋白或者重組蛋白的質(zhì)量和純度不符合要求。在這里,來自CUSABIO的蛋白表達(dá)工程師根據(jù)他們開發(fā)重組蛋白的經(jīng)驗(yàn)總結(jié)出了幾個(gè)有用的提示,可以幫助你做出明智的決策。

第一條:重組蛋白的生產(chǎn),在這篇文章中,我們旨在闡明重組蛋白的定義以及如何生產(chǎn)重組蛋白。

第二條:如何選擇合適的表達(dá)載體?

表達(dá)載體是一種DNA分子,它攜帶特定的基因進(jìn)入宿主細(xì)胞,并利用細(xì)胞的蛋白質(zhì)合成機(jī)制來產(chǎn)生由該基因編碼的蛋白質(zhì)。表達(dá)載體可使外源基因在宿主細(xì)胞中高效表達(dá),經(jīng)過多年的發(fā)展,表達(dá)載體已成為一種成熟而受歡迎的生物技術(shù)。在重組蛋白生產(chǎn)過程中是一種基本成分。正如標(biāo)題所示,本文主要總結(jié)了幾個(gè)有用的技巧來選擇合適的表達(dá)載體。

第三條:如何表達(dá)具有生物活性的蛋白質(zhì)?

根據(jù)重組蛋白的不同應(yīng)用,對(duì)其生物活性有不同的要求。但是我們?nèi)绾未_保蛋白質(zhì)的產(chǎn)生具有生物活性呢?本文將圍繞這個(gè)主題,并提供一些解決方案。除了以上文章,我們還收集了一些重組蛋白的常見問題。您可以單擊以下鏈接查看。http://www.51tesewang.com/technology-91.html。此外,我們還為我們的客戶提供重組蛋白表達(dá)服務(wù),您可以點(diǎn)擊這里獲取更多信息。注:如果您對(duì)CUSABIO的蛋白質(zhì)有任何疑問,涉及到蛋白質(zhì)的價(jià)格、交貨、質(zhì)量等,您可以點(diǎn)擊橙色按鈕為我們?cè)诰€留言。

引用資料

Recombinant Severe acute respiratory syndrome coronavirus 2 RNA-dependent RNA polymerase(NSP12) cited in "SARS-CoV-2 hijacks cellular kinase CDK2 to promote viral RNA synthesis". Signal transduction and targeted therapy, 2023

Recombinant Mouse Mixed lineage kinase domain-like protein(Mlkl) cited in "OASL phase condensation induces amyloid-like fibrillation of RIPK3 to promote virus-induced necroptosis". Nature cell biology, 2023

Recombinant Mouse Proto-oncogene c-Fos(Fos) cited in "Dihydroartemisinin imposes positive and negative regulation on Treg and plasma cells via direct interaction and activation of c-Fos". Communications biology, 2023

Recombinant Human Keratin, type I cytoskeletal 18(KRT18) cited in "Calcitonin gene-related peptide ameliorates sepsis-induced intestinal injury by suppressing NLRP3 inflammasome activation". International immunopharmacology, 2023

Recombinant Human Protein Wnt-5a (WNT5A) cited in "ATBF1 is a potential diagnostic marker of histological grade and functions via WNT5A in breast cancer". BMC Cancer, 2022

Read More >>